Topics

Panagin Pharmaceuticals Inc. Company Profile

19:00 EST 28th January 2020 | BioPortfolio

Panagin Pharmaceuticals Inc., a privately-held biotech company, specializes in the discovery, research, development and commercialization of saponin based anti-cancer drugs. Panagin's proprietary new drug candidates show strong anti-cancer properties against various advanced, metastatic, multi-drug resistant cancers. Panagin's research and clinical programs focus on life-threatening diseases, such as lung cancer, pancreatic cancer, and brain metastases from various original sites.
Panagin's goal is to provide pharmaceutical treatment for cancers using saponin technology. Its growth strategy is to develop one or more of its portfolio candidates to Phase II clinical trials for cancer indications that currently do not have effective treatment.
Panagin has completed pre-IND communications with US FDA. In 2004, the Company is preparing to file IND and conduct Phase I clinical studies of PBD-2131B (oral) for the treatment of lung cancer and other solid tumours. In 2005, Panagin plans to advance another drug candidate PAM-200 to the clinic for the treatment of brain metastases from original lung cancer.
Pandimex™ (PBD-2131B injection), has received conditional market approval in China for the treatment of advanced cancers of lung, breast, pancreas, stomach and colon-rectum. Pandimex™ can be used as a single agent and combination agent with paclitaxel. A Panagin-controlled joint venture is formed to market Pandimex™, and to upgrade its regulatory status to a full NDA approval.

Location

Unit 110-116, 11800 River Road
Richmond
British Columbia
V6X 1Z7
Canada

Contact

Phone: 604.303.9988
Fax: 604.303.9926
Email: info@panagin.com


News Articles [533 Associated News Articles listed on BioPortfolio]

FDA approves nine generic versions of Pfizer's Lyrica

The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the commercial green light to not one, but nine different analogue therapies. The...

Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium’s UCB to b...

Belgium’s UCB to buy Ra Pharmaceuticals for $ 2.1bn

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium’s UCB to b...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Leadership Update

BOSTON, MA / ACCESSWIRE / January 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec.....

GW Pharmaceuticals: Überzeugende Quartalszahlen

Kulmbach (www.aktiencheck.de) - GW Pharmaceuticals-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär", nimmt in einer aktuellen Aktienanalyse die GW Pharmaceuticals....

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors

BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin tech...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin tech...

Sobi to buy Dova Pharmaceuticals in $915m deal

The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals The post So...

Drugs and Medications [0 Results]

None

PubMed Articles [119 Associated PubMed Articles listed on BioPortfolio]

Mytilidae as model organisms in the marine ecotoxicology of pharmaceuticals - A review.

Growing production and consumption of pharmaceuticals is a global problem. Due to insufficient data on the concentration and distribution of pharmaceuticals in the marine environment, there are no app...

Occurrence and ranking of pharmaceuticals in the major rivers of China.

Residual pharmaceuticals have received widespread attention worldwide due to their continuous release and potential hazard to the environment. As a result of rapid development and a large population, ...

Analysis, occurrence and removal of pharmaceuticals in African water resources: A current status.

Pharmaceuticals are organic compounds used in medicines for alleviation of pain. Since 2017, there has been a steady increase on the availability of information on contamination of water resources cau...

Prioritization of pharmaceuticals in water environment in China based on environmental criteria and risk analysis of top-priority pharmaceuticals.

Numerous studies have shown that a wide range of pharmaceuticals are present in the environment and many of their adverse biological effects on the aquatic ecosystem and human health are unknown. Due ...

Biological-activity-based prioritization of pharmaceuticals in wastewater for environmental monitoring: G protein-coupled receptor inhibitors.

Pharmaceuticals raise concerns for aquatic species owing to their biological activities. It is estimated that nearly 40% of marketed pharmaceuticals target G protein-coupled receptors (GPCRs). Using a...

Clinical Trials [251 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1408 Associated Companies listed on BioPortfolio]

Panagin Pharmaceuticals Inc.

Panagin Pharmaceuticals Inc., a privately-held biotech company, specializes in the discovery, research, development and commercialization of saponin based anti-cancer drugs. Panagin's proprietary new ...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

Avanir Pharmaceuticals

AVANIR Pharmaceuticals, formerly LIDAK Pharmaceuticals, is a development stage company organized to discover, develop, and market novel therapeutic products to treat human diseases.

More Information about "Panagin Pharmaceuticals Inc." on BioPortfolio

We have published hundreds of Panagin Pharmaceuticals Inc. news stories on BioPortfolio along with dozens of Panagin Pharmaceuticals Inc. Clinical Trials and PubMed Articles about Panagin Pharmaceuticals Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Panagin Pharmaceuticals Inc. Companies in our database. You can also find out about relevant Panagin Pharmaceuticals Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record